Silence Puts Preclinical Cancer Drug on Back Burner to Advance Candidates with Newer Delivery Tech | GenomeWeb

By Doug Macron

Silence Therapeutics this week announced that it has put on hold the development of its preclinical cancer drug Atu137 after determining that the drug's potential clinical profile is “too similar” to the company's phase I solid tumor therapy Atu027.

As a result, the firm said it will shift its attention onto an as-yet undisclosed preclinical candidate that makes use of another one of its proprietary delivery technologies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.